About
Anti T cell Immunotoxin
Areas of Focus
Categories
Small Molecule PharmaceuticalVirginia, DC, DE & Maryland
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
259
By Phase
PHASE2: 2PHASE1/PHASE2: 2
By Status
UNKNOWN: 2TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT02943642Lead Sponsor
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
PHASE2Unknown
162 participants
Started: Jan 31, 2017 · Completed: May 31, 2020
NCT02990416Lead Sponsor
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
PHASE1/PHASE2Unknown
63 participants
Started: Jan 31, 2017 · Completed: Jun 30, 2018
NCT01888081Lead Sponsor
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
PHASE1/PHASE2Terminated
2 participants
Started: Feb 28, 2014
NCT00611208Lead Sponsor
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
PHASE2Completed
32 participants
Started: Jan 31, 2008 · Completed: Nov 30, 2016
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...